A 59-year old gentleman with transformation of myelodysplastic syndrome
to acute megakaryoblastic leukemia was treated with standard intensive
chemotherapy. His poor outcome was attributed to advanced age,
aggressive disease biology, underlying myelodysplastic syndrome, poor
response to induction chemotherapy, high lactate dehydrogenase and lack
of good cytogenetic and molecular mutations.